These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32131606)

  • 41. Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health?
    Belcheva A; Irrazabal T; Martin A
    Bioessays; 2015 Apr; 37(4):403-12. PubMed ID: 25601287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases.
    Belizário JE; Faintuch J; Garay-Malpartida M
    Mediators Inflamm; 2018; 2018():2037838. PubMed ID: 30622429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics.
    Principi N; Cozzali R; Farinelli E; Brusaferro A; Esposito S
    J Infect; 2018 Feb; 76(2):111-120. PubMed ID: 29291933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel polyphenolic prebiotic and probiotic formulation have synergistic effects on the gut microbiota influencing Drosophila melanogaster physiology.
    Westfall S; Lomis N; Prakash S
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):441-455. PubMed ID: 29644870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
    Yang YJ; Ni YH
    J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neonatal Gastrointestinal and Respiratory Microbiome in Cystic Fibrosis: Potential Interactions and Implications for Systemic Health.
    Madan JC
    Clin Ther; 2016 Apr; 38(4):740-6. PubMed ID: 26973296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients-A Narrative Review.
    He S; Lin F; Hu X; Pan P
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The integumentary system and its microbiota between health and disease.
    Inchingolo AD; Cazzolla AP; Di Cosola M; Greco Lucchina A; Santacroce L; Charitos IA; Topi S; Malcangi G; Hazballa D; Scarano A; Lorusso F; Inchingolo AM; Inchingolo F; Dipalma G
    J Biol Regul Homeost Agents; 2021; 35(2 Suppl. 1):303-321. PubMed ID: 34281327
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: a randomized double-blind controlled clinical trial.
    Lee SJ; Bose S; Seo JG; Chung WS; Lim CY; Kim H
    Clin Nutr; 2014 Dec; 33(6):973-81. PubMed ID: 24411490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal dysbiosis and probiotic applications in autoimmune diseases.
    de Oliveira GLV; Leite AZ; Higuchi BS; Gonzaga MI; Mariano VS
    Immunology; 2017 Sep; 152(1):1-12. PubMed ID: 28556916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathogenesis and therapeutic opportunities of gut microbiome dysbiosis in critical illness.
    Cho NA; Strayer K; Dobson B; McDonald B
    Gut Microbes; 2024; 16(1):2351478. PubMed ID: 38780485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?
    Rinaldi E; Consonni A; Guidesi E; Elli M; Mantegazza R; Baggi F
    Ann N Y Acad Sci; 2018 Feb; 1413(1):49-58. PubMed ID: 29341125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of Probiotics in Human Gut Microbiome-Associated Diseases.
    Kim SK; Guevarra RB; Kim YT; Kwon J; Kim H; Cho JH; Kim HB; Lee JH
    J Microbiol Biotechnol; 2019 Sep; 29(9):1335-1340. PubMed ID: 31434172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications.
    de Moreno de LeBlanc A; LeBlanc JG
    World J Gastroenterol; 2014 Nov; 20(44):16518-28. PubMed ID: 25469019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microbiota and Dose Response: Evolving Paradigm of Health Triangle.
    Coleman M; Elkins C; Gutting B; Mongodin E; Solano-Aguilar G; Walls I
    Risk Anal; 2018 Oct; 38(10):2013-2028. PubMed ID: 29900563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Restoring the Microbiome in Critically Ill Patients: Are Probiotics Our True Friends When We Are Seriously Ill?
    Manzanares W; Langlois PL; Wischmeyer PE
    JPEN J Parenter Enteral Nutr; 2017 May; 41(4):530-533. PubMed ID: 28445681
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.